Category: 1098184-12-3

A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 1098184-12-3, Name is (S)-2-(((Benzyloxy)carbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid, molecular formula is C15H19NO5. In a Patent£¬once mentioned of 1098184-12-3, SDS of cas: 1098184-12-3

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS

Compounds of Formula I: and salts thereof in which R 1 , R 2 , R 2a , R 3 , n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.SDS of cas: 1098184-12-3. In my other articles, you can also check out more blogs about 1098184-12-3

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1098184-12-3,(S)-2-(((Benzyloxy)carbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid,as a common compound, the synthetic route is as follows.

tert-Butyl(3S,8aR)-3-[(1R)-1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl]hexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (380 mg) obtained in Example 5 (ii) was dissolved in 4M hydrogen chloride-ethyl acetate solution (5 mL), and the solution was stirred at room temperature for 18 hr. The precipitate resulting from the reaction mixture was collected by filtration. To the collected precipitate were added tetrahydrofuran (5 mL), N-ethyl-N-(1-methylethyl)propan-2-amine (0.497 mL), (2S)-{[(benzyloxy)carbonyl]amino}(tetrahydro-2H-pyran-4-yl)ethanoic acid (418 mg) and 1-hydroxybenzotriazole (218 mg). To this mixture was added 1-ethyl-3-3-dimethylaminopropyl)carbodiimide hydrochloride (310 mg), and the mixture was stirred at room temperature for 18 hr. To the reaction mixture was added water (50 mL), and the mixture was extracted with ethyl acetate (200 mL). The organic layer was washed with saturated brine (50 mL), dried over anhydrous magnesium sulfate, and filtered, and the filtrate was concentrated to give an oil. This oil (500 mg) was dissolved in methanol (3 mL), 20% palladium-carbon (100 mg, 20 wt %) was added thereto, and the mixture was stirred at room temperature for 4 hr under a hydrogen atmosphere (3 atm). The insoluble material was filtered off through a celite pad, and the filtrate was concentrated to give an oil., 1098184-12-3

1098184-12-3 (S)-2-(((Benzyloxy)carbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid 66926961, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; US2011/34469; (2011); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics